Evidence map›Paper›PMID 39699210›Full record

ArticleAntimicrobial agents and chemotherapy2025

Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients.

Nilesh Kumta, Aaron J Heffernan, Menino Osbert Cotta, Xin Liu, Suzanne Parker, Steven Wallis, Amelia Livermore, Therese Starr, Wai Tat Wong, Gavin M Joynt and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nilesh KumtaThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.ORCID 0000-0002-9272-342X
Aaron J HeffernanThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.ORCID 0000-0002-7929-9812
Menino Osbert CottaThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.ORCID 0000-0002-2058-2314
Xin LiuThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
Suzanne ParkerThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.ORCID 0000-0002-6124-7475
Steven WallisThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
Amelia LivermoreThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
Therese StarrThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
Wai Tat WongDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.
Gavin M JoyntDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.
Jeffrey LipmanThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
Jason A RobertsThe University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.ORCID 0000-0001-6218-435X

Funding

Intensive Care Foundation (ICF)Royal Brisbane and Women's Hospital Foundation (RBWH Foundation)
6 · The paper itself

Abstract

Ventriculitis in neurocritical care patients leads to significant morbidity and mortality. Antibiotic dose optimization targeting pharmacokinetic/pharmacodynamic (PK/PD) exposures associated with improved bacterial killing may improve therapeutic outcomes. We sought to develop and apply a population PK model in infected critically ill patients to determine optimal piperacillin-tazobactam (PTZ) dosing regimens to achieve target cerebrospinal fluid (CSF) exposures. Neurosurgical patients with external ventricular drains and receiving PTZ treatment were recruited and had plasma and CSF samples collected and assayed. A population PK model was developed using plasma and CSF piperacillin and tazobactam concentrations. Eight patients were recruited. Median age was 59 years, median weight was 70 kg, and five patients were female. The median creatinine clearance was 84 mL/min/1.73 m

Indexed as

Anti-Bacterial AgentsCerebral VentriculitisPiperacillin, Tazobactam Drug CombinationAdultAgedCritical IllnessFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedPiperacillinTazobactamAnti-Bacterial AgentsPiperacillinPiperacillin, Tazobactam Drug CombinationTazobactamantibioticscerebrospinal fluidcritical illnesspharmacokinetic/pharmacodynamicpiperacillin-tazobactamventriculitisventriculostomy-associated infection

Identifiers

PMID39699210
PMCPMC11823673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.